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Abstract 
 
Introduction: 
In age-related macular degeneration (AMD), induced pluripotent stem cell (iPSC)-based therapies have 
advanced from the bench to human trials over the last decade. This novel therapy has the potential to 
replace or regenerate damaged tissue, such as retinal pigment epithelium (RPE) to treat geographic 
atrophy or to limit choroidal neovascularization.  
 
Areas covered:  
Induced PSCs can be derived from the introduction of transcription factors to adult cells under specific 
cell culture conditions, which can then be differentiated into various cell types, including RPE cells. 
Induced PSC-derived RPE cells exhibit ion transport, membrane potential, polarized vascular endothelial 
growth factor (VEGF) secretion and gene expression that is similar to native RPE cells and have 
principally been investigated as subretinal transplants to replace or replenish diseased RPE. It remains to 
be seen if stem cell-based RPE cells can replicate the myriad of functions, including immunomodulatory 
effects, of native RPE cells in the human eye.   
  
Expert opinion: 
Induced PSC-based RPE transplantation is a promising investigational therapy in the treatment of AMD, 
however significant progress is required prior to broad application and major pathophysiological hurdles 
may eventually limit its success in AMD. 
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1. Background 
Age-related macular degeneration (AMD) is one of the leading causes of blindness globally. By the 
year 2020, an estimated 196 million people will have AMD and 11 million will have significant vision loss 
[1]. AMD can broadly be categorized into atrophic and neovascular (nAMD) forms. Atrophic AMD is 
characterized by the development of drusen and retinal pigment epithelial (RPE) changes early in the 
disease course, and with loss of RPE (geographic atrophy, GA) and associated severe vision loss in 
advanced disease. Currently no effective treatment exists for GA. Neovascular AMD is characterized by 
choroidal neovascularization (CNV) causing central vision loss from macular exudation; subsequently, 
despite treatment, fibrosis and/or RPE atrophy develop in nearly half of patients by 2 years, resulting in 
severe permanent central vision loss [2]. 
Anti-vascular endothelial growth factor (anti-VEGF) therapy is currently the standard of care for 
nAMD.  The original ANCHOR (Antibody for the Treatment of Predominantly Classic CNV in AMD Study) 
and MARINA (Minimally Classic/Occult Trial of the Anti-VEGF Antibody Ranibizumab in the Treatment of 
nAMD) trials of monthly ranibizumab respectively yielded 11.3 and 7.2 Early Treatment of Diabetic 
Retinopathy Study (ETDRS) letters of improvement at one year [3, 4]. However, the subsequent open 
label extension HORIZON trial ( An Open-Label Extension Trial of Ranibizumab for Choroidal 
Neovascularization Secondary to Age-Related Macular Degeneration) showed insidious loss of vision, 
yielding a mean visual acuity (VA) improvement of only 2 ETDRS letters after four years [5].  Similarly, in 
a follow-up study of the CATT (Comparison of AMD Treatment Trials) trial, patients experienced a mean 
loss of 3 ETDRS letters five years after initiating anti-VEGF treatment [6]. “Real world” studies of anti-
VEGF therapy in nAMD have reported even less favorable visual outcomes [7-19].  Several of these “real 
world” studies, based on chart reviews, electronic medical records (EMR) or claims analysis, 
demonstrate that nAMD patients generally lose vision by the 2- to 5-year time point despite anti-VEGF 
therapy [9-13, 16, 19, 20]. While the cause of these discrepancies between “real world” studies and 
RCTs is unknown, patient characteristics and undertreatment are implicated [7-9, 13, 14].  Several of 
these “real world” nAMD studies observed a 20-30% loss to follow-up in the first year [8, 10, 14, 16], 
highlighting the treatment burden. Additionally, some “real world” nAMD studies suggest that poor 
visual outcomes account for patient drop out [10, 12, 14] and that despite treatment, patients with 
better baseline VA experience greater loss of vision than patients with worse baseline VA [12, 14, 16, 
18].  This experience over the past decade demonstrates the limitations of anti-VEGF agents and the 
unmet need for more effective therapy.   
  Stem cells, currently under investigation for the treatment of AMD, are characterized by the ability 
to differentiate into multiple cell lineages and an unlimited self-renewal capacity [21]. Pluripotent stem 
cells (PSCs), by definition, are able to differentiate into all endodermal, mesodermal and ectodermal 
lineages. Induced pluripotent stem cells (iPSCs) are a subtype of pluripotent stem cells and are intriguing 
in that they can be derived from a previously differentiated cell source and have the potential for 
reduced ethical controversy over human embryonic stem cell (hESC)-based therapies, and may negate 
immunological issues associated with hESC-based therapies. The eye is an ideal candidate for stem cell 
research because the clear ocular media allows for direct visualization of transplanted cells and the eye 
is a relatively immune privileged site; furthermore, the size of the eye requires smaller quantities of 
therapeutic tissue in comparison to other organs. In AMD, stem cells have the potential for replacing or 
regenerating lost tissue, such as RPE replacement to treat GA and to limit CNV. They have the potential 
to produce growth factors and cytokines such as brain derived neurotrophic factor (BDNF) that have a 
supportive paracrine effect on local structures within the macula. Exciting research into stem cell-based 
therapy for AMD has been performed over the last several decades and will be reviewed here. Emphasis 
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will be placed on research into iPSCs, but context will be provided through a discussion of other stem-
cell based therapies. 
 
2. AMD pathogenesis 
A basic understanding AMD pathology provides context to better evaluate the therapeutic role of 
stem cell-based therapies. AMD pathogenesis involves a complex mixture of structural and functional 
changes as a result of aging [22], chronic oxidative stress [23] and pathologic inflammation [23]. This 
etiologic milieu eventually results in the clinical appearance of drusen and RPE changes, and eventually 
vision threatening GA and CNV.  
Aging results in numerous changes to the RPE, Bruch’s membrane (BM) and choriocapillaris (CC), 
which could adversely affect the health of any transplanted stem cells. With age, the RPE accumulates 
residual bodies containing lipofuscin, resulting in a reduced phagocytic capacity and an impairment of 
lysosomal function [24, 25]. A generalized age-related loss of RPE cells increases the metabolic demand 
on each cell [26]. Bruch’s membrane is a 5-layered structure between the RPE and CC. With age, the 
thickness [27], the amount of non-collagenous proteinaceous material [28] and the amount of lipids 
increases [29].  The BM’s central elastic layer becomes thinned and calcified [30], increasing the risk of 
BM breaks that facilitate CNV ingrowth through a breach of the anti-angiogenic barrier [31].  
Additionally, BM heparan sulfate quantities decrease with age, resulting in less Complement Factor H 
(CFH) binding; as discussed below, this factor moderates the complement cascade and decreased local 
levels may potentiate the inflammatory component of AMD pathogenesis [32]. These structural and 
biochemical changes affect the transport of molecules and growth factors across BM and likely directly 
affect the interaction between BM and both the RPE and CC, including any stem cell derived RPE 
transplant. The choriocapillaris is the innermost layer of the choroid and supplies the oxygen and 
nutrients and eliminates the waste of the BM, RPE and photoreceptors. The CC density and vessel 
diameter decreases with age along with the total choroidal thickness [28, 33]. Choriocapillaris 
endothelial density decreases [34], supporting the notion that vascular changes may contribute to AMD. 
Overall, these age-related changes of the RPE-BM-CC complex contribute to AMD pathogenesis and are 
one of several factors necessary for pathologic manifestations.  
Oxidative stress is likely a major contributor to the development of AMD based on epidemiologic 
and clinical studies [23].  Tobacco use is a well-known risk factor for AMD.  On a mechanistic level, 
chronic accumulation of reactive oxygen species (ROS) can be detrimental to an organism through 
oxidization of DNA, proteins and lipids [35]. ROS can be generated through exposure to UV light, ionizing 
radiation and normal cellular enzymatic reactions [36]. The balance towards more oxidative stress is 
present in patients with AMD. Levels of plasma glutathione, an antioxidant, are low in patients with 
AMD [37].  ROS formation is high due to the high oxygen tension observed in the retina [36] and also 
due to the constant exposure to light [36]. Additionally, nutritional supplementation with the 
antioxidants Vitamin C and Vitamin E reduces the risk of progression of moderate AMD [38]. Cumulative 
oxidative stress over decades likely contributes to the impaired function of RPE-BM-CC complex. 
Additionally, of particular relevance to stem cell-based therapies, any subretinally transplanted cells will 
be exposed to the same oxidative stress, potentially affecting cellular behavior and survival. 
An impaired inflammatory response is a key component in AMD pathogenesis, potentially further 
complicating stem cell based transplantation. Patients with AMD are known to have elevated systemic 
inflammatory biomarkers such as C-reactive protein (CRP), interleukin-6 (IL-6), and homocysteine [39, 
40], and surgically excised CNV has been shown to contain inflammatory cells [41]. The inflammation 
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appears to be mediated through the complement cascade of the immune system.  Normally, the 
complement cascade detects and destroys blood born bacteria.  It can be activated via an antibody-
dependent pathway (the “classical pathway”), an antibody-independent pathway (the “alternate 
pathway”), or on binding to specific carbohydrates on the surface of microorganisms (the “lectin” 
pathway). Complement was first implicated in the pathogenesis of AMD in 2005, when a common 
variant in complement factor H (CFH) gene was noted to be strongly associated with AMD, with 
individuals homozygous for the risk allele possessing a 7.4 fold increased risk [42, 43]; several other 
genetic variants in complement genes have since been associated with AMD [44-46]. CFH is a natural 
inhibitor of factor C3 activation, which is central to the three pathways.  Complement is involved in 
drusen formation , and genetic variations in CFH can lead to less effective modulation of complement 
pathway activity, leading to greater precipitation of complement protein observed in drusen [47]. The 
final common pathway of complement activation, factor C5, is cleaved to form key terminal fragments 
(C5a and C5b-9) regardless of which pathway (classical, alternate or lectin) induced their generation. The 
C5a fragment, observed in drusen of AMD patients, is an important inflammatory activator, recruiting 
inflammatory cells and inducing vascular endothelial growth factor (VEGF) expression from RPE cells 
[48]. C5b is involved in the formation of the membrane attack complex (MAC: C5b-9), which causes cell 
death through disruption of the cell membrane. In humans, deposition of MAC in Bruch’s membrane 
and choriocapillaris increases significantly with aging and with AMD [49]. When choroidal endothelial 
cells are exposed to MAC, cell lysis occurs and the surviving cells express VEGF and matrix 
metalloproteinases (MMP); thus, MAC deposition in the choriocapillaris may play a role in atrophic and 
neovascular AMD, respectively [50]. Consequently, both C5a and MAC may promote CNV, and this is 
supported by experimental models of CNV, in which inhibition of C5a and MAC formation prevents the 
development of CNV [51, 52].  
AMD pathogenesis is a chronic, complex process that affects the RPE-BM-CC complex and stem cell-
based therapies will need to overcome key structural and functional changes. Additionally, if placed 
subretinally, any transplant will be exposed to a toxic environment, potentially affecting the survival and 
physiology of the transplanted cells.  
 
3. Induced pluripotent stem cells 
Human embryonic stem cells (hESCs) were first cultured in 1998 and have the potential to 
differentiate into all cell types [53]. They are a promising source for stem-cell based therapy but 
raise potential ethical considerations due to their harvesting during embryogenesis when there is 
potential for full development.  In 2006, Takahashi and Yamanaka discovered a method of inducing a 
pluripotent state from terminally differentiated mouse fibroblasts, potentially addressing this issue. 
The introduction of four transcription factors, Oct3/4, Sox2, c-Myc and Klf4 to adult murine 
fibroblasts under embryonic cell culture conditions, resulted in an induced pluripotent stem cell 
(iPSC) state as confirmed by the ability to differentiate into all three germ layers upon 
transplantation into adult mice and mouse embryos [54]. One year later, two separate groups were 
able to create iPSCs from adult human cells, another major scientific milestone [55, 56].   
Numerous advances in the efficiency and safety of iPSC generation has occurred over the 
last decade.  Various groups have developed methods for improving the efficiency of pluripotency 
induction through the use of factors such as valproic acid [57], SV40 large T antigen [58], and 
microRNA [59]. The development of iPSCs has also become safer.  The original use of Myc 
transcription factor in the formation of iPSCs created concern that constitutively active Myc, an 
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oncogene, could result in tumor formation. This problem was solved in 2008 by Nakagawa et al. 
when they demonstrated a method of iPSCs production in mouse and human fibroblasts without the 
use of Myc [60]. Similarly, the safety of using retroviral vectors for creating iPSCs, and concern about 
retroviral integration into the DNA with unpredictable sequelae such as creating a tumorigenic state, 
was overcome through numerous methods including the use of non-integrating episomal vectors 
[61], adenoviruses [62], the Sendai virus [63], piggyback transposition [64], minicircles [65], mRNA 
transfection [66, 67], microRNAs [68], transfection of a single multiprotein expression vectors [69], 
chemicals [70] and reprogramming proteins [71], among other techniques. The landscape of 
methods to effectively and efficiently induce a pluripotent state is expanding rapidly and a thorough 
discussion is beyond the scope of this review.  
These advances over the last decade helped pave the way for the translation of iPSC-based 
animal and human studies. In addition to cell therapy, iPSCs have other applications, including 
disease modeling and drug discovery.  
 
4. Retinal pigment epithelium transplantation 
  RPE replacement is of interest in AMD therapeutics research given its numerous key roles in 
retinal support and function, as well as its pathophysiologic roles in AMD. This section reviews RPE 
physiology, the history of RPE transplantation, preclinical studies, and the most recently published 
human studies. 
4.1. Retinal pigment epithelium physiology 
The RPE, a monolayer of hexagonal cells, plays numerous roles in retinal homeostasis.  It is a 
polar layer with the apical portion facing the outer segments of the photoreceptors and the basal 
surface facing BM. The polarity of RPE cells aids in the transport of ions, water and metabolic 
products from the subretinal space to the CC [72]. It also helps in the delivery of glucose and fatty 
acids to the outer retina [72]. Voltage-dependent ion conductance at the apical membrane creates 
the appropriate ion composition in the subretinal space necessary for photoreceptor excitability 
[72]. Tight junctions help maintain polarity in addition to forming the outer blood-retinal barrier 
[73]. RPE cells apically project microvilli that facilitate retinal adhesion and processing of shed outer 
photoreceptor segments. These shed photoreceptor outer segments are processed by the RPE 
through phagocytosis and subsequently recycled to the photoreceptors or eliminated to the CC [74].  
Multiple steps in the retinoid cycle are performed by the RPE cells and provide photoreceptors with 
11-cis-retinal [75]. Melanin is abundantly found in RPE cells and functions by preventing light 
reflection and as a free radical scavenger [72].   
The RPE physiologically secretes numerous growth factors. Pigment epithelium-derived 
factor (PEDF) has anti-angiogenic and neurotrophic properties and is principally secreted apically by 
the RPE [72]. VEGF, at low levels, is secreted on the basal surface of the RPE and prevents 
endothelial cell apoptosis of the CC [72]. Tissue inhibitors of metalloproteinases (TIMP-1 and TIMP-
3) are secreted to stabilize the endothelium, Bruch’s membrane and the CC extracellular matrix [72]. 
Fibroblast growth factor and ciliary neurotrophic factors are secreted in response to RPE damage 
and have neuroprotective roles. Contributions to immune privilege and inflammation modulation is 
performed through the secretion of interleukins and cytokines and through the presentation of cell 
membrane proteins [72, 76]. Consequently, the RPE plays multiple roles in the physiology of the CC 
and retina through the secretion of growth factors, while also facilitating ocular immune privilege 
through the secretion of interleukins and cytokines [72, 77].  
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These paracrine functions of the RPE are critical for the health of the neurosensory retina. 
This discussion is pertinent because most stem cell based therapies in AMD strive to replace or 
supplement diseased RPE cells.  While critical functions dependent on proper orientation and 
structure may be challenging to replicate with stem-cell based therapy, the paracrine functions 
could potentially be more easily supplanted.  
4.2. History of adjuvant retinal pigment epithelium transplantation in choroidal neovascular 
membrane resection 
This section provides a brief discussion on the history of RPE transplants and the relevance 
to stem-cell based transplantation. Subfoveal neovascular membrane resection was one of 
numerous investigational therapies for nAMD in the 1990s [78, 79]. A major limitation of this 
procedure was the associated extraction of RPE and the subsequent development of GA with a poor 
visual prognosis [80-82]. To limit this atrophy, investigators attempted various methods of adjuvant 
RPE transplantation following CNV resection, including homologous fetal RPE transplantation [83], 
homologous adult RPE transplantation [84, 85], macular translocation [86], autologous RPE 
transplantation [84, 87, 88], choroidal-RPE transplantation [89, 90], and Bruch’s membrane-RPE 
transplantation [91]. With the advent of anti-VEGF therapy, the investigative fervor of RPE 
transplantation subsided, but numerous lessons can be gleaned from those studies. 
Intraoperatively, manipulation of RPE grafts makes transplantation technically difficult. 
Maaijwee et al. published a series of 84 RPE and choroidal translocation procedures, in which 56 
were associated with an inadequate positioning or incomplete flattening of the graft [92]. The graft 
was often partly folded or wrinkled, and 12 cases required extraction and reinsertion [92]. Joussen 
et al. noted that of 45 eyes receiving an autologous translocation of peripheral choroid and RPE, two 
patients intraoperatively and one patient postoperatively were observed to have an upside-down 
insertion of the graft [89]. These technical difficulties will similarly be encountered in stem-cell 
based therapies utilizing subretinal RPE sheets that require precise orientation, but not in stem cell-
based therapies utilizing intravitreal or subretinal cellular suspensions.   
Immediately post-operatively, a high rate of subretinal hemorrhage occurred in several 
published series. MacLaren et al. noted that 4 of 12 patients who underwent an autologous RPE and 
choroidal transplantation experienced a subretinal hemorrhage within 1 week of surgery [93]. 
Similarly, Joussen et al. observed that of 45 eyes treated with autologous choroidal and RPE 
transplantation, 18 experienced a massive subretinal hemorrhage postoperatively [89]. Stem-cell 
based therapies that create iatrogenic subretinal spaces (i.e. retinal detachment “blebs” via 
vitrectomy) and inject transplants through retinotomies may pose similar risks. However, a likely 
contributing factor to subretinal hemorrhage was the CNV resection performed prior to 
transplantation, which all ongoing stem cell-based studies currently avoid. 
A major limitation in early RPE transplantation studies was the rejection of transplants. In a 
study of non-immunosuppressed allogenic fetal subretinal RPE transplants, the majority of eyes with 
atrophic AMD rejected the transplant and all patients with nAMD rejected the transplant [85]. 
Despite the relative immune privilege of the subretinal space, the immunogenicity of fetal RPE cells 
resulted in an unacceptable rate of rejection. The higher rejection rate for nAMD patients was 
thought by authors to be due new blood vessels disrupting the blood-retinal barrier. Tezel et al., 
seeking to overcome this immunological hurdle, investigated 12 patient receiving allogenic, adult 
RPE transplants and added triple immunosuppression with corticosteroids, cyclosporine and 
azathioprine postoperatively [94]. None of the 12 transplants experienced rejection [94], suggesting 
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the need for immunosuppression in these allogenic transplants. In contrast, autologous transplants 
with low immunogenicity, were found to have low rates of rejection [88]. Stem cell-based therapy 
will need to account for the immune response to transplanted tissue, particularly if allogenic tissue 
is utilized.  
Several case series have noted a high rate of proliferative vitreoretinopathy (PVR) following 
RPE transplant. For example, Joussen et al. observed that 17 of 45 eyes that underwent an 
autologous choroidal and RPE transplantation experienced PVR [89]. Several other case series 
involving autologous choroidal and RPE transplantation and macular translocation surgeries have 
noted high rates of PVR [90, 95-97]. PVR is likely fostered by the extensive manipulation of the 
retina, RPE and choroid during harvesting and may also be related to extensive manipulation of the 
graft during insertion through the macular retinotomy. In comparison, allograft RPE transplant 
studies suggest lower rates of PVR [98], likely due to smaller retinotomies and  without the need to 
harvest tissue from the surgical eye. We suspect that stem-cell based therapies will have similar PVR 
rates as the allograft studies because of less manipulation of RPE and choroid and smaller 
retinotomies. 
4.3. Preclinical stem-cell based retinal pigment epithelium studies 
Studies investigating adjuvant RPE transplants during CNV resection performed during the 
1990s and early 2000s demonstrated the feasibility of subretinal transplantation, as well as the 
associated challenges. This section will review preclinical studies of stem cell-based RPE therapy, 
which demonstrated proof of mechanism prior to human studies. 
 The manufacturing of stem cell-based RPE transplants requires RPE cells to be created from 
progenitor cells, a complex process that has undergone significant evolution over the last two 
decades. One of the earliest and simplest methods of RPE differentiation was to allow pluripotent 
stem cells to undergo “spontaneous” differentiation [99].  While producing a highly pure RPE yield, 
the spontaneous method was lengthy and inefficient, and supplementation with various factors has 
improved efficiency [100, 101]. Early on, RPE differentiation utilized co-culture with mouse cells 
[102], which raised reasonable ethical and clinical concerns if this resulting RPE were to be 
implanted into human eyes. This hurdle was overcome in 2012 by using human fibroblast feeder 
cells [103] as opposed to non-human feeder cells, and later by methods obviating the need for 
feeder cells [104]. Differentiation of desired cells is a time-consuming process, and from 2013-2016, 
numerous investigators have published successively more efficient methods of RPE differentiation 
[105-111].  
Improved efficiency and effectiveness in the production of stem cell-derived RPE cells led to 
numerous animal studies. Stem cell-based RPE grafts have been successfully transplanted 
subretinally in rats [101, 112-115], mice [116], rabbits [117] and pigs [118]. The successful surgical 
implantation [112-114, 116-118], survival [112-114, 116-118], and in several publications the 
integration [117] and functional rescue of retinal function in AMD animal models [112, 113, 116, 
117] paved the way for human trials.  
Stem cell-derived RPE cells are mostly considered “RPE cells” based on morphology, 
immunostaining, electron microscopic analysis and a few functional studies. Kokkinaki et al., 
demonstrated that iPSC-derived RPE cells exhibit ion transport, membrane potential, polarized VEGF 
secretion and gene expression that is similar to native RPE [119]. Others have noted that iPSC-
derived RPE cells have similar mRNA expression, protein expression and rod outer segment 
phagocytosis when compared to fetal human RPE cells [106]. In contrast, Sugino et al. noted that 
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ESC-derived RPE behaved differently than fetal RPE when placed on aged human Bruch’s membrane 
[120]. Additionally, Liao et al. demonstrated that the molecular signature of hESC-derived RPE cells 
are different from fetal RPE cells and an even greater difference existed between human iPSC-
derived RPE cells and fetal RPE cells [121]. It remains to be seen if stem cell-based RPE cells can 
replicate the myriad of functions, including immunomodulatory effects, of native RPE cells in the 
human eye. 
4.4. Human studies of human embryonic stem cell-derived retinal pigment epithelium 
transplantation 
The first human studies of stem cell-based RPE transplants in AMD were published in 2012 
[122].  Schwartz et al. performed two prospective clinical trials assessing the safety and tolerability 
of subretinal transplantation of hESC-derived RPE cells in patients with Stargardt macular dystrophy 
and dry AMD [123]. Nine subjects with atrophic AMD and nine with Stargardt macular dystrophy 
were included and all had VA measuring from 20/200 to hand motion [123]. Patients underwent 
pars plana vitrectomy, followed by injection of 150 microliters of RPE cellular suspension into the 
subretinal space at preselected sites of transition between diseased and healthy retina [123]. 
Patients received either 50,000 cells, 100,000 cells or 150,000 cells and were immunosuppressed 
with tacrolimus and mycophenolate mofetil from 1 week before surgery until 12 weeks following 
surgery [123]. 
Following surgery, 72% of patients had increased subretinal pigmentation at the location of 
transplantation, suggesting presence of the injected cells [123]. OCT imaging of this hyperpigmented 
region revealed findings consistent with a layer of cells lining Bruch’s membrane [123]. At 6 months, 
the VA in AMD patients improved by 15 letters in four eyes, 11-14 letters in two eyes and remained 
stable in three eyes [123]. No significant changes were seen in visual field, static perimetry, 
electroretinography, or reading speed [123]. No signs of acute rejection were noted, such as 
prominent lymphocyte infiltration, acute or chronic moderate grade non-infectious uveitis, 
hyperacute rejection, cystoid macular edema, encapsulation of the transplanted cells, or whitening 
of the transplanted area [123].  No eyes developed abnormal growth suggestive of a teratoma, a 
tumor comprised of 2 or more germ layers which could originate from stem cells; and no eyes 
developed PVR or a retinal detachment, although four patients developed a cataract and one 
developed endophthalmitis [123]. At four years, no teratoma formation or abnormal differentiation 
of cells occurred [124]. 
These results suggest the tolerability of subretinal stem cell-derived RPE therapy. Adverse 
events were acceptable and, importantly, there was no evidence of tumor formation or rejection. A 
follow-up study is currently underway that will include patients with better baseline VA, which 
should theoretically yield better outcomes given lower amounts of preexisting RPE-BM-CC complex 
damage.  
In 2015, Song et al. published preliminary results of subretinal hESC-derived RPE 
transplantation in two patients with advanced atrophic AMD and two patients with Stargardt 
disease [125]. In two patients, surgical complications included difficulty creating a retinotomy site 
and a retinal bleb encroaching the fovea, both of which required a secondary retinotomy site [125]. 
In one patient, a small subretinal hemorrhage was noted postoperatively that resolved by 13 weeks 
[125]. Immunosuppression was stopped in one patient because of kidney damage and 
myelosuppression [125]. No patients developed a teratoma or immune rejection [125]. This study 
demonstrated the technical difficulties of performing subretinal surgery as well as the systemic risks 
[Type here] 
 
of immunosuppression. Similar to Schwartz et al., importantly, no rejection or teratoma formation 
was noted. 
4.5.  Human studies of pluripotent stem cell-based retinal pigment epithelium transplantation 
 The use of iPSC-derived RPE transplants in human trials has lagged behind the use of ESCs. The 
first human trial using iPSCs-derived RPE subretinal transplants was initiated by RIKEN, a research 
institute in Kobe, Japan in September 2014 [126]. A 70-year-old Japanese woman became the first 
person in the world to receive an iPSC-derived therapy [127]. Of note, she did not receive 
immunosuppression [127], in comparison to the patients in ESC-derived RPE transplantation studies 
[123, 125]. Additionally, the patient demonstrated no adverse effects at one year, as the 
transplanted sheets remained intact and her vision decline had stabilized [128, 129]. 
 This study proved short-lived when it was suspended the subsequent year [126]. The reasons for 
the suspension were multifactorial and included regulatory changes in Japan, but of particular 
concern was the development of mutations in the second patient’s iPSCs that were not detectable 
in the patient’s original fibroblasts [126]. The genomic instability of iPSCs has been documented by 
other investigators [130] and the potential tumorigenicity of these cells needs to be considered in 
human trials. Of note, and emphasized by the investigators of the RIKEN study, mutations are not 
necessarily tumorigenic [127].  
 In 2016, RIKEN planned to resume the study, with a significant modification. Instead of 
autologous cells, they are investigating HLA-matched allogenic iPSC-derived RPE cells [126]. These 
cells will not only be verified for genomic stability but the process of cell production will be 
expedited [126]. The use of autologous cells are estimated to require three months to develop and 
cost approximately $1,000,000 from harvesting to intraocular implantation [127]. Thus, the use of 
HLA-matched allogenic stem cell derived transplants are more likely to succeed financially and have 
the potential to be safer. A downside of using allogenic cells is the increased risk of rejection and the 
likely need for immunosuppression. 
 Another study using iPSC-derived RPE cells is currently underway at Moorfields Eye Hospital in 
England (Table 1) and other groups in the United States are working on garnering FDA approval for a 
US-based study [127]. 
 
5. Retinal progenitor cell transplantation 
  An alternative to subretinal RPE transplantation is the subretinal transplantation of retinal 
progenitor cells. In 2002, Zhao et al. published a method of differentiating ESCs into retinal neurons 
[131, 132]. As in stem cell-based RPE research, improved methods of photoreceptor differentiation 
occurred over the ensuing decade [133, 134]. Additionally, various groups described methods of 
differentiating iPSCs into photoreceptors [100, 135, 136], allowing for potentially fewer ethical and 
immunologic concerns. 
  Numerous preclinical studies have demonstrated the ability of neural precursor cells to 
integrate into the retina of animal models. Precursor cells have been derived from a variety of animal 
sources including adult rat brain [137, 138], rat retina [139], mouse embryo [140-143], mouse brain 
[144], mouse spinal cord [145], mouse retina [146], adult mouse induced iPSCs [147], human brain [148, 
149] and human embryos [150]. These various cell sources have been injected into the vitreous cavities 
and subretinal spaces of numerous rat and mouse retinal degeneration models for AMD [137-154]. 
Overall, the transplanted progenitor cells have demonstrated the ability to survive, integrate and 
develop various degrees of retinal differentiation [137-139, 142, 144-146, 150-152, 154, 155]. Several 
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small animal studies have even demonstrated improved retinal function following transplantation [149, 
154-158].  In large animals, investigators have published the subretinal hESC-based photoreceptor 
transplantation in healthy squirrel monkeys, and found the transplants were able to survive 3 months 
and demonstrated in vivo imaging evidence of axonal projections extending into the host retina, optic 
nerve and retrolaminar optic nerve [159].   
  Subretinal transplantation of photoreceptors is traditionally thought to result in a degree of 
migration and integration of the transplant within the host retina.  Recently, however, research into 
preclinical models of photoreceptor transplantation have elucidated a novel mechanism of host-
transplant cellular interaction.  Various authors have demonstrated that transplanted photoreceptors 
transfer proteins and/or RNA with the host tissue, without fusion of nuclei and with significantly less 
integration of transplanted photoreceptors than previously thought [160-162]. This novel finding has 
brought into question the prior understanding and conclusions of photoreceptor transplantation in 
animal models and the mechanism of how these transplants improve vision, in particular if there is a 
significant degree of integration of transplanted cells. Additionally, this discovery reveals a possible 
therapeutic mechanism, whereby transplanted cells transfer needed proteins and genes rather than 
direct tissue replacement.   
  In 2006, MacLaren et al., published a landmark study identifying the ideal ontogenetic stage of 
donor cells for successful rod photoreceptor transplantation [163].  They harvested retinal progenitor 
cells from normal mice and subretinally transplanted them into adult mice, neonatal mice and in three 
disease models [163]. They varied the age of maturation of transplanted cells and noted that progenitor 
cells that were aged outside the ideal ontogenetic stage did not integrate into the retina [163].  These 
findings highlight a catch-22 situation, where if the transplant is not terminally differentiated, then the 
eye has increased risk of teratoma formation; in contrast, if the transplant is terminally differentiated, 
then it is unlikely to properly integrate into the host retina.  
  Regarding safety, the intraocular transplantation of non-terminally differentiated pluripotent 
stem cell-based photoreceptor progenitors increases the risk of teratoma formation in several animal 
models [146, 155]. This observation is not surprising because of the unlimited replicative potential of 
pluripotent stem cells and their ability to differentiate into all cell types. This is in contrast to the 
transplantation of terminally-differentiated RPE cells, which through differentiation, lose the ability for 
further differentiation or replication. Surprisingly, even neurally-selected mouse ESCs can induce tumor 
formation after subretinal transplantation [140]. In this study, tumors developed 2 months following 
surgery even though 2 weeks after engraftment there was no hint of pathology [140]. The authors 
speculated that despite attempting for a pure selection of neural precursor cells, a few of the less 
differentiated cells were likely injected into animal eyes as well, resulting in the teratoma formation 
[140]. If non-terminally-differentiated stem-cell based therapies are to be used in humans, the 
possibility of less-differentiated cells contaminating the treatment sample must be considered.  
    
  The major limitation of these animal studies is the difficulty in simulating complex human 
pathologies such as AMD. Animal models of human ocular pathology usually have one pathologic 
process resulting in visual impairment. In contrast, AMD results in damage the CC, BM and RPE as well as 
local immunological changes, which is difficult to replicate in an animal model.  Additionally, numerous 
studies investigated transplantation into young animal eyes [137, 139, 141, 148, 149], which have a 
different microenvironment than aged eyes. Thus, the translatability of retinal progenitor cell 
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transplantation in animal models to human studies has significant limitations and there have been no 
human studies to date.  
 
 
6 Challenges to effective  transplantation 
6.1 Surgical complications 
Subretinal surgery is technically difficult and exposes patients to potential risks. Song et al., 
while performing subretinal transplants of ESC-derived RPE cells, had difficulty in creating a 
retinotomy site in two of four patients, requiring the creation of a secondary retinotomy site at a 
different location [125]. Each retinotomy site theoretically increases the risk of complications, 
including scotoma, hemorrhage, retinal detachment and PVR.  In one patient, the retinotomy bleb 
encroached the fovea, requiring another retinotomy site [125]. In contrast, Schwartz et al., did not 
publish similar difficulties in 18 patients [123]. The methods of each investigator were similar, with 
both performing a pars plana vitrectomy, inducing of posterior vitreous detachment and injecting 
150 microliters of suspended cells into the subretinal space using a 38-G cannula. However, it is 
likely that these authors had small differences in technique or surgical instruments to account for 
these differences. . Regardless, surgical challenges will undoubtedly be encountered with subretinal 
transplantations and these risks need to be weighed against the potential benefits.  
Theoretically, fewer surgical complications should be encountered with bone marrow stem 
cell (BMSC)-derived therapy, an alternative stem cell source. BMSC-based treatments have largely 
been investigated as intravitreal therapies because the transplant is injected for a supportive 
paracrine effect, as opposed to a cell replacement role. However, postoperatively, patients may be 
at increased risk of proliferation of cells within the vitreous, as was noted in several animal models 
[164, 165] as well as in humans [166], and particularly with mesenchymal stem cells.  
Several case reports of adverse events following BMSC-based therapy have been published. 
Following intravitreal injection of CD34-positive stem cells, a 71-year-old female patient developed a 
visually significant epiretinal membrane within four months [167]. Another patient, a 60-year-old 
man with Stargardt disease, developed a retinal detachment 2 months following subretinal injection 
of autologous bone marrow-derived mesenchymal stem cells [168]. Most recently, Kuriyan et al., 
published a tragic case series of three patients who experienced retinal detachment and profound 
loss of vision following adipose tissue-derived mesenchymal stem cell intravitreal transplants at one 
center in Florida [166]. Consequently, despite the more invasive nature of the subretinal approach 
with iPSC therapy, it may pose lower overall risk than the intravitreal approach used with BMSC-
derived stem cells, which has led to significant proliferation and fibrosis within the vitreous cavity, 
followed by retinal detachment in a subset of patients.  
 
6.2 Transplant immunology 
The eye is relatively immunologically privileged, making it an intriguing option in the 
investigation of stem cell-based therapies [169-172]. The mechanism for this immune privilege is 
complex and incompletely understood, but the RPE monolayer likely plays a critical role and is 
known to express and secrete transforming growth factor-beta, somatostatin, thrombospondin, 
PEDF and CD86, all of which either directly or indirectly modulate the immune response [173]. On a 
cellular level, RPE cells can induce T cell apoptosis and modulate macrophage activation by PEDF 
production [174, 175].  
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Ocular pathology can alter the immunological balance, as increased immunogenicity was 
observed in RPE transplant studies during the 1990s. Patients with nAMD had a significantly higher 
rate of RPE transplant rejection than those with atrophic AMD, possibly due to a CNV-induced break 
in the blood-retinal barrier [85]. In addition to a break in the blood-retinal barrier, patients with 
atrophic AMD had a high rate of rejection, albeit lower than in nAMD, suggesting a separate 
mechanism for ocular immunological impairment [85]. Immune suppression with corticosteroids, 
cyclosporine and azathioprine eliminated the immune rejection of adult RPE allografts [94], and this 
method will likely be necessary in humans who receive allograft transplants.  
Induced PSC-derived cells have demonstrated reduced immunogenicity [176, 177], one of 
their advantages over ESC-based therapy. Furthermore, the use of autologous iPSCs is hypothesized 
to reduce the risk of immune rejection due to self-identification of implanted cells. The disadvantage 
of autologous induction of pluripotency followed by the differentiation of cells into acceptable 
transplants is its time-consuming and expensive nature.  An alternative role for iPSCs is allogenic 
transplantation using HLA-matched iPSCs, similar to HLA-matched organ transplantation. Preclinical 
studies have supported this idea by demonstrating that iPSC-derived RPE cells lack a T cell response 
[178] and a non-immunosuppressed animal model utilizing MHC-matched subretinal iPSC-derived 
RPE transplants showed no evidence of rejection [179]. In contrast, an animal model using MHC-
mismatched transplants resulted in an immune attack around the graft and nearby retinal tissue 
[179]. In preparation for human studies, generation of iPSCs from donors who are HLA-matched 
with ~20% of the Japanese population has been developed [180].   
6.3 Systemic immunosuppression 
Immunosuppression improves the survival of transplanted tissues but carries a significant 
risk. Schwartz et al. utilized low-dose tacrolimus (target blood levels of 3-7 ng/mL) and 
mycophenolate mofetil (MMF, ranging 0.5 g – 2 g orally/day) one week prior to transplantation 
[123]. At six weeks, tacrolimus was discontinued and MMF was continued for an additional six 
weeks [123]. Several patients needed to discontinue or modify therapy due to adverse events [123]. 
One patient developed severe shortness of breath, moderate fatigue, moderate diarrhea and severe 
stomach aches, and consequently MMF was discontinued [123]. A second patient developed a UTI, 
resulting in the discontinuation of both medications [123]. A third patient developed 
endophthalmitis and immunosuppression was stopped [123].  
Song et al. similarly noted significant adverse events from systemic immunosuppression 
[125]. Their immunosuppressive protocol was comparable to Schwartz et al., with MMF and 
tacrolimus started one week prior to surgery and continued for 6 weeks postoperatively [125]. 
Subsequently, tacrolimus was discontinued and MMF was continued an additional 7 weeks [125]. In 
one patient, immunosuppression was stopped at 4 weeks postoperatively due to acute kidney 
injury, elevated potassium levels, bone marrow suppression and diarrhea [125]. Another patient 
developed pneumonia, which was treated successfully with oral antibiotics, and immunosuppression 
was not stopped [125]. A third patient developed herpetic vesicles on the right arm, which was 
possibly related to MMF immunosuppression, but immunosuppression was not stopped [125].  
These studies demonstrate that immunosuppressive medications are not without risks. The 
use of autologous or allogenic, HLA-matched iPSC-derived cell therapy may reduce the immune 
response to transplanted cells and minimize the need for potent and long-term 
immunosuppression. The ideal immunosuppressive medications, duration and dose remains to be 
determined.  
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6.4 Aging Bruch’s Membrane 
AMD pathogenesis results in significant changes to the retina, RPE, BM and choroid, which 
may limit successful subretinal RPE transplantation.  Given the close anatomic and functional 
interactions between transplanted RPE and BM, the changes to BM are of prime importance. In vitro 
studies have demonstrated that aged BM alters the gene expression profile of human RPE [181], 
reduces the likelihood of attachment to BM [182] and increases RPE apoptosis [183, 184]. 
Various attempts have been attempted to overcome these limitations. Extensive research 
has been conducted to develop an effective film to support stem cell-based RPE cell growth and 
transplantation [185-193]. The goals of this film are to create an artificial attachment for stem-cell 
based RPE cells that would negate the need for attachment to diseased BM, as well as providing 
structural and physiological support. The major limitation of the film is its potential adverse effect 
on subretinal physiology and, for films that biodegrade, the ability of RPE cells to attach to 
remaining BM following dissolution of the film. The use of films has transitioned to clinical research, 
as can be seen in Table 1, with two groups using a film on which RPE cells are transplanted. 
Other methods to improve RPE cellular adherence to aged BM include altering integrin 
expression on RPE cells [194, 195], modifying the extracellular matrix of RPE cells prior to 
transplantation [196], and modifying native BM of treated eyes prior to transplantation [197]. While 
demonstrating preclinical effectiveness, these methods have not yet translated to human studies.  
 
7 Ongoing studies 
Table 1 includes a list of ongoing or recently completed studies investigating various types of stem cell-
derived therapies in atrophic AMD and nAMD. A wide variety of cell sources are included in these 
studies.  
 
Table 1. List of ongoing or recently completed stem-cell based therapies in AMD. 
Type of Stem 
Cell Therapy 
Transplantation 
Method 
Ocular 
Pathology 
Clinicaltrials.gov 
Number 
Sponsor Study phase 
Autologous 
induced 
pluripotent stem 
cell-derived RPE 
cells 
Subretinal atrophic 
AMD 
NCT02464956 Moorfields Eye 
Hospital NHS 
Foundation 
Trust 
Phase 1  
Allogenic HLA-
matched induced 
pluripotent stem 
cell-derived RPE 
cells 
Subretinal nAMD -- RIKEN Phase 1 
Autologous 
bone-marrow 
derived stem 
cells 
Intravitreal nAMD, 
atrophic 
AMD, 
Stargardt 
NCT01518127 University of 
Sao Paulo 
Phase 1 and 
2 
Autologous 
bone-marrow 
derived stem 
cells 
Intravitreal atrophic 
AMD 
NCT02016508 Al-Azhar 
University 
Phase 1 and 
2 
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Autologous bone 
marrow-derived 
stem cells 
Retrobulbar, 
sub-Tenon, 
intravenous, 
intravitreal, 
subretinal 
Various, 
including 
AMD 
NCT01920867 Retina 
Associates of 
South Florida 
Not 
documented  
Autologous 
bone-marrow 
derived stem 
cells 
Intravitreal atrophic 
AMD 
including 
other 
retinal 
pathologi
es 
NCT01736059 University of 
California, 
Davis 
Phase 1  
      
Human central 
nervous system 
stem cells 
Subretinal atrophic 
AMD 
NCT01632527 StemCells, Inc. Phase 1 and 
2 
Human 
embryonic stem 
cell-derived RPE 
Subretinal AMD, 
Stargardt 
NCT02749734 Southwest 
Hospital, China 
Phase 1  
Human 
embryonic stem 
cell-derived RPE 
Subretinal  atrophic 
AMD 
NCT02755428 Chinese 
Academy of 
Sciences 
Phase 0 
Human 
embryonic stem 
cell-derived RPE 
Subretinal atrophic 
AMD 
NCT01674829 CHA Biotech 
CO., Ltd 
Phase 1 and 
2 
OpRegen: Human 
embryonic stem-
cell derived RPE 
Subretinal atrophic 
AMD 
NCT02286089 Cell Cure 
Neurosciences, 
Ltd. 
Phase 1 and 
2  
Human 
embryonic stem 
cell-derived RPE 
Subretinal atrophic 
AMD 
NCT01344993 Astellas 
Institute of 
Regenerative 
Medicine 
Phase 1 and 
2  
Human 
embryonic stem 
cell-derived RPE 
on a parylene 
membrane 
Subretinal atrophic 
AMD 
NCT02590692 Regenerative 
Patch 
Technologies, 
LLC 
Phase 1 and 
2  
Arm 1: Human 
embryonic stem 
cell-derived RPE 
suspension and 
Arm 2: Human 
embryonic stem 
Subretinal nAMD, 
atrophic 
AMD, 
Stargardt 
NCT02903576 Federal 
University of 
Sao Paulo 
Phase 1 and 
2  
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cell-derived RPE 
seeded on a 
substrate 
 
8 Conclusion 
The limitations of anti-VEGF therapy in the treatment of nAMD and the lack of effective treatment 
for nonexudative AMD demonstrate the need for new therapies. Stem cell-based therapies are an 
intriguing therapeutic option and have been extensively investigated over the last several decades. 
Induced PSC therapies are of particular interest because of their reduced immunogenicity and their 
potential for reduced ethical controversy over hESC-based therapies.  A decade of preclinical studies 
improving the safety and efficiency of iPSC-derived RPE transplants paved the way for human trials. 
The investigational treatment of a 70-year-old Japanese woman was the first published utilization of 
iPSCs in humans, and is a major investigational milestone. The major limitation of applying stem cell-
based therapies to patients with AMD is the chronic and complex disease process that needs to be 
overcome. Despite these limitations, RIKEN and Moorefields Eye Hospital are planning on further 
studies utilizing iPSCs in the treatment nAMD and non-neovascular AMD, and their results will be 
eagerly awaited.  
 
9 Expert Opinion 
The use of iPSCs was first performed on a Japanese female with end-stage AMD, and this marked a 
major milestone as the first application of iPSC-based therapy in humans. The preceding decade of 
advancement in the generation and differentiation of iPSCs, which started in 2006 with the discovery of 
Yamanaka factors, as well as previous research into RPE transplantation, has allowed for the rapid 
translation of bench research to clinical trials.  
Induced PSC-derived transplants are a promising investigational therapy in AMD research due to the 
potential for reduced ethical controversy over hESC-based therapies, as well as their reduced 
immunogenicity. A dampened immune response could improve the survival and function of transplants 
as well as potentially minimize the need for chronic powerful perioperative systemic 
immunosuppressive agents. Research into hESCs has demonstrated the potential harms associated with 
immunosuppression following subretinal transplantation, as reviewed above.  
Disadvantages of iPSC-based therapies include their time-consuming and expensive production, 
particularly for autologous transplants, as well as their relative genomic instability. The use of 
autologous cells are estimated to require three months to develop and cost approximately $1,000,000 
from harvesting to intraocular implantation [127]. The use of allogenic HLA-matched cells allows for a 
more efficient and economical application, as well as allowing for a more thorough investigation of 
potential mutations, and consequently likely represents the future of iPSC-based therapies for human 
AMD research. RIKEN stopped their trial due to genomic instability noted in a batch of iPSC-based RPE 
tissue.  Despite the unclear clinical significance of this finding, they halted further research and 
revamped their methods prior to continuing their trial.  
Induced PSCs have principally been investigated as subretinal transplants to replace or replenish 
diseased RPE cells. The advantages of this approach is that RPE cells are damaged in AMD and their 
replacement could theoretically improve photoreceptor function and survival. However, the limitations 
are numerous. Native RPE cells have a number of functions and it remains to be seen if iPSC-derived RPE 
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cells are able to replicate these roles. Arguably, transplanted cells may not need to replicate all functions 
to be therapeutically successful, but it remains to be seen if they are able to replicate the essential roles 
necessary for a reduction in disease progression. Additionally, the replacement of RPE cells may not 
overcome the AMD-related damage of the CC and BM, and AMD pathology might progress despite a 
successful transplantation. Furthermore, the long-term survival and proper functioning of transplanted 
cells in an environment of increased oxidative stress, increased immunogenicity and surrounding tissue 
damage remains to be seen.  
Induced PSCs may have a more promising role in utilizing paracrine effects than direct tissue 
replacement. It will be interesting to learn if iPSC-derived tissue can be genetically modified to produce 
locally-acting growth factors. We suspect that stem-cell based therapies for AMD, including iPSCs-based 
therapies, will likely move in the direction of utilizing paracrine effects. This is due to the complexity of 
AMD pathogenesis and the questionable benefit of replacing a defective layer such as the RPE when the 
surrounding tissue is damaged and exposed to increased oxidative stress and pathologic 
immunogenicity. Pathologies that are less chronic and cause less extensive tissue damage may be more 
amenable to direct tissue replacement. Alternatively, advancements in our understanding of 
photoreceptor transplant interaction with host tissue, in particular the transfer of proteins and/or RNA 
from transplanted photoreceptors to host tissue as was discovered recently, may hold promise. 
Additionally, choroidal cell generation from iPSCs has recently been published [198], and a combination 
of tissues may eventually be more effective.  
Despite our view that the paracrine effects of transplanted tissue holds the most promise for AMD 
treatment at this moment, rapid advancements in the field of stem cell biology and research just beyond 
the horizon could easily change this perspective.  Overall, the research into iPSC-based therapy is in its 
nascency. Significant progress is required prior to broad application and major pathophysiological 
hurdles may eventually limit its success in AMD. 
 
Article Highlights 
• In both neovascular and advanced non-neovascular age-related macular degeneration (AMD), 
stem cell therapy has the potential to improve on current therapeutic limitations. 
• Induced pluripotent stem cells (iPSCs) are promising in that they are derived from adult human 
cells, ameliorating the need for embryonic stem cells (ESCs) and have the potential for reduced 
immunogenicity.  
• Retinal pigment epithelial (RPE) tissue, derived from iPSCs, has undergone the most extensive 
research in AMD therapy and holds the most promise for application in humans. 
• Previous studies investigating adjuvant RPE transplantation combined with choroidal 
neovascular membrane resection have provided excellent lessons for the application of iPSC-
based therapies. 
• The use of iPSCs was first performed on a Japanese female with end-stage AMD, and this 
marked a major milestone as the first application of an iPSC-based therapy in humans. 
• Significantly more research is needed to determine the efficacy and safety of transplantation of 
stem cells in AMD. 
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